SURMODICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 19, 2023, Surmodics, Inc. (the "Company") issued a press release (the "Press Release") disclosing communications that the Company received from the U.S. Food and Drug Administration related to the Company's application for premarket approval of the SurVeil™ drug-coated balloon. A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under Section 18, nor shall such information be deemed incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d)          Exhibits.

        Exhibit
        Number     Description
          99.1       Press Release dated January 19, 2023
        104        Cover Page Interactive Data File (embedded within the Inline XBRL
                   document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses